Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

NCT05111561 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

42

Enrollment

NIH

Sponsor class

Stopped Other - Amendment needed to add new dose level.

Conditions

Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Triple-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm

Interventions

DRUG: BET Bromodomain Inhibitor ZEN-3694
DRUG: Binimetinib
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

National Cancer Institute (NCI)